The findings are published in the December issue of Biochemical Pharmacology.
Inflammation is necessary for maintaining good health – without inflammation, wounds and infections would never heal. However, persistent and constant inflammation can damage tissue and organs, and lead to diseases such as sepsis. Sepsis affects approximately 750,000 Americans each year, 28 to 50 percent of whom die from the condition, and costs the nation’s healthcare system nearly $17 billion annually. It is a potentially life-threatening complication of an infection or injury, and occurs when chemicals released into the bloodstream to fight the infection trigger inflammation throughout the body. The result is that organs become damaged, including liver, heart, lungs, kidney and brain. If excessive damage occurs, it may be irreversible. For years, Feinstein Institute researchers have been trying to identify ways to halt persistent and constant inflammation.
Tanshinones have been used for treatment of cardiovascular and cerebrovascular diseases. Based on research on mice conducted by Haichao Wang, PhD, and his colleagues, including Kevin J. Tracey, MD, and Andrew E. Sama, MD, at the Feinstein Institute, tanshinone IIA sodium sulfonate (TSN-SS) effectively inhibited the release of HMGB1 outside of cells. HMGBI is a deoxyribonucleic acid (DNA) protein that mediates inflammation and, if over expressed, causes sepsis. Furthermore, Dr. Wang and his colleagues previously discovered that inhibition of HMGB1 by TSN-SS protected against sepsis-induced animal mortality and cardiovascular dysfunction in animals.
“Dr. Wang’s research on TSN-SS has uncovered details that offer a new mechanism for intracellular drug delivery,” said Sarah Dunsmore, Ph.D., of the National Institutes of Health’s National Institute of General Medical Sciences, which partially supported the work. “These findings have broad significance and implications for treating a variety of conditions, including cancer, sepsis and Alzheimer’s disease.”
The NIH grant numbers that supported this study are AT005076 and GM063075.
The Feinstein Institute, in alliance with the Cleveland Clinic, is exploring opportunities to commercialize patent technologies relating to the use of TSN-SS in the treatment of human diseases.
“This novel therapy opens up more applications for the use of Chinese traditional medicine in western medicine, and it is my hope that it will be tested for efficacy in sepsis clinical trials in the near term.” said Dr. Wang.
The Feinstein Institute and its parent company, the North Shore-LIJ Health System, have been dedicated to studying and treating sepsis. In 2010, the Feinstein Institute hosted an international Merinoff Symposium dedicated to sepsis. This symposia attracted researchers, policymakers and other opinion leaders from around the world who identified that sepsis should be categorized as a medical emergency, treatable with fluids and antibiotics within one hour of recognition. The health system mounted an aggressive sepsis prevention and early identification initiative that has reduced the health system’s sepsis mortality rate by 35 in the past four years, which translates into thousands of saved lives.
About The Feinstein Institute for Medical Research
Headquartered in Manhasset, NY, The Feinstein Institute for Medical Research is home to international scientific leaders in many areas including Parkinson’s disease, Alzheimer’s disease, psychiatric disorders, rheumatoid arthritis, lupus, sepsis, human genetics, pulmonary hypertension, leukemia, neuroimmunology, and medicinal chemistry. The Feinstein Institute, part of the North Shore-LIJ Health System, ranks in the top 5th percentile of all National Institutes of Health grants awarded to research centers. For more information visit www.FeinsteinInstitute.org
Media Contact: Emily Ng